Department of Otorhinolaryngology, Institute of Clinical Medicine, University of Oulu, PO Box 5000, FIN-90014 Oulu, Finland.
J Clin Endocrinol Metab. 2010 Sep;95(9):4268-75. doi: 10.1210/jc.2010-0537. Epub 2010 Jun 9.
Data on the incidence of pituitary adenomas (PAs) are scant and outdated. A population-based regional cohort with thorough case identification was used to evaluate the incidence of clinically detected PAs in the era of magnetic resonance imaging.
The objective of the study was to describe the age- and sex-specific incidence of all PA subgroups, with data on incidentally found PAs, pituitary apoplexies, and time trends.
DESIGN, SETTINGS, AND PATIENTS: This was a retrospective descriptive analysis of PA patients diagnosed during 1992-2007 in Northern Finland (NFi).
World Health Organization 2000-standardized incidence rates (SIRs) of PAs per 100,000 were measured.
The final cohort consisted of 355 PAs. The incidence rates of the Oulu University Hospital regional district were used as a reference to assess the applicability of our case finding over the rest of NFi. Incidence rates of all PA subgroups except microprolactinomas were statistically equal between these areas; thus, all presented SIRs are based on the NFi's cohort except Oulu University Hospital regional district-based prolactinomas and PAs overall. Overall SIR of PAs was higher (4.0 per 100,000) than in previous reports. Prolactinomas had the highest SIR: 2.2 per 100,000, followed by clinically nonfunctioning PAs (1.0) and GH-secreting (0.34), ACTH-secreting (0.17), and TSH-secreting (0.03) PAs. The gender-specific SIR was 2.2 per 100,000 in males and 5.9 per 100,000 in females. Pituitary apoplexy occurred as a presenting symptom in 11% of clinically nonfunctioning PA patients. The SIR of incidentally discovered PAs increased significantly from 1992-1999 to 2000-2007 (0.59 to 1.6, respectively; P < 0.01), which accounted for the perceived increasing trend in the overall SIR of PAs (3.8 to 4.2; P > 0.05).
关于垂体腺瘤(PA)的发病率数据很少且已经过时。本研究采用基于人群的区域性队列,通过彻底的病例识别,评估磁共振成像时代临床上发现的 PA 的发病率。
本研究的目的是描述所有 PA 亚组的年龄和性别特异性发病率,包括偶然发现的 PA、垂体卒中以及时间趋势的数据。
设计、设置和患者:这是对 1992-2007 年在芬兰北部(NFi)诊断为 PA 的患者进行的回顾性描述性分析。
以世界卫生组织 2000 年标准发病率(SIR)表示,每 10 万人中有多少例 PA。
最终队列包括 355 例 PA。使用奥卢大学医院地区的发病率作为参考,评估我们在 NFi 其余地区发现病例的适用性。除微泌乳素瘤外,所有 PA 亚组的发病率在这些地区之间统计学上是相等的;因此,除了奥卢大学医院地区的泌乳素瘤和整个 NFi 的 PA 之外,所有呈现的 SIR 都基于 NFi 的队列。PA 的总体 SIR 高于以往报告(4.0/10 万)。泌乳素瘤的 SIR 最高:2.2/10 万,其次是临床上无功能的 PA(1.0)和 GH 分泌瘤(0.34)、ACTH 分泌瘤(0.17)和 TSH 分泌瘤(0.03)。男性的性别特异性 SIR 为 2.2/10 万,女性为 5.9/10 万。垂体卒中作为临床上无功能 PA 患者的首发症状占 11%。偶然发现的 PA 的 SIR 从 1992-1999 年到 2000-2007 年显著增加(分别为 0.59 和 1.6;P <0.01),这解释了临床上发现的 PA 的总体 SIR 增加的趋势(从 3.8 到 4.2;P >0.05)。